ReviewMaterials today. Bio2025
Functionalized albumin nanoparticles: A multifunctional platform for enhanced brain drug delivery.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Animal- and Plant-Derived Protein Nanocarriers for the Delivery of Natural Compounds in Breast Cancer Chemoprevention.Molecules (Basel, Switzerland) · 2026Review
- Design and In Vitro Evaluation of Cyclodextrin-Functionalized Albumin Nanoparticles for Intranasal Carbamazepine Brain Delivery.Pharmaceutics · 2026Article
- Albumin Nanoparticles as Multifunctional Carriers for Advanced Therapeutics.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin nanoparticles represent a unique protein-based platform for brain drug delivery, leveraging albumin intrinsic properties including exceptional biocompatibility, prolonged 19-day circulation half-life, and endogenous transport pathways via gp60 and FcRn receptors. While the blood-brain barrier restricts ∼98 % of therapeutic agents from reaching the central nervous system, functionalized albumin nanoparticles overcome this challenge by hijacking native transport mechanisms at the barrier interface. This review delivers an extensive evaluation of various methodologies for functionalizing albumin nanoparticles via covalent and non-covalent approaches aimed at improving barrier permeability, enhancing targeting precision, and enabling controlled drug release. Particular emphasis is given to ligand-based modifications that enable active receptor targeting and stimuli-responsive systems triggered by the brain microenvironment. Unlike reviews covering general nanocarrier systems, this work specifically focuses on the distinctive properties and functionalization strategies unique to albumin-based platforms. Albumin multiple reactive groups provide a versatile scaffold for functional ligand conjugation, distinguishing it from synthetic nanocarriers. Despite persisting challenges, including formulation consistency and clinical translation enhancement, functionalized albumin nanoparticles provide versatile solutions with promising advancements for treating brain tumors, neuroinflammatory disorders, and neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.